CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.22BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.6660xvs all stocks
52-Week Change
77.58%vs all stocks
Market Capitalization
7.22BUSDvs all stocks (USD)
Enterprise Value
6.93BUSDvs all stocks (USD)
Forward P/E
-25.45xvs Biotechnology peers
Price to Book (MRQ)
28.39xvs Biotechnology peers
Enterprise to EBITDA
-17.11xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-58.82%vs Biotechnology peers
Return on Equity (TTM)
-167.77%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Aug 28, 2026Gross Profit (TTM)
-207.41MUSDvs all stocks (USD)
EBITDA (TTM)
-404.88MUSDvs all stocks (USD)
Net Income (TTM)
-408.59MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-296.83MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-153.88MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-384.64MUSDvs all stocks (USD)
Pre-tax Income
-377.94MUSDFY2025 · Dec 31, 2025Net Income
-377.94MUSDFY2025 · Dec 31, 2025EBIT
-371.05MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-369.39MUSDFY2025 · Dec 31, 2025Research & Development
208.44MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
176.21MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
6.89MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.29USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.29USDFY2025 · Dec 31, 2025Basic Shares Outstanding
114.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
114.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-377.94MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-300.85MUSDFY2025 · Dec 31, 2025Free Cash Flow
-301.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
327.33MUSDFY2025 · Dec 31, 2025Interest Paid
6.07MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-377.94MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.66MUSDFY2025 · Dec 31, 2025Stock-based Compensation
75.60MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.68MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
208.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.06MUSDFY2025 · Dec 31, 2025Capital Expenditures
-602.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-98.01MUSDFY2025 · Dec 31, 2025Sale of Investments
317.30MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
218.69MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
74.66MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-25.52MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
140.80MUSDFY2025 · Dec 31, 2025Shares Outstanding
121.60MSharesUpdated Aug 28, 2026Float Shares
104.09MSharesUpdated Aug 28, 2026Shares Short
18.22MSharesUpdated Aug 28, 2026Short Ratio
18.07daysvs all stocks
Short % of Shares Outstanding
18.67%vs all stocks
% Held by Insiders
0.77%vs all stocks
% Held by Institutions
117.52%vs all stocks
Total Cash (MRQ)
492.09MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.04USDUpdated Aug 28, 2026Total Debt (MRQ)
203.83MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.8032xvs Biotechnology peers
Current Ratio (MRQ)
7.02xvs Biotechnology peers
Book Value per Share (MRQ)
2.09USDUpdated Aug 28, 2026Total Assets
404.27MUSDvs all stocks (USD)
Total Current Assets
385.15MUSDFY2025 · Dec 31, 2025Total Liabilities
158.78MUSDFY2025 · Dec 31, 2025Total Non-current Assets
19.13MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
103.36MUSDFY2025 · Dec 31, 2025Total Current Liabilities
55.42MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
323.53MUSDFY2025 · Dec 31, 2025Other Short-term Investments
44.04MUSDFY2025 · Dec 31, 2025Accounts Payable
10.30MUSDFY2025 · Dec 31, 2025Short-term Debt
5.55MUSDFY2025 · Dec 31, 2025Long-term Debt
103.36MUSDFY2025 · Dec 31, 2025Common Stock (Book)
108.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.30BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
245.49MUSDvs all stocks (USD)
52-Week Low
27.07USDUpdated Aug 28, 202652-Week High
61.76USDUpdated Aug 28, 202652-Week Change
77.58%vs all stocks
Beta
0.6660xvs all stocks
50-Day MA
52.70USDUpdated Aug 28, 2026200-Day MA
47.01USDUpdated Aug 28, 2026Avg 10-Day Volume
1.18MSharesUpdated Aug 28, 2026Avg 30-Day Volume
1.09MSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-3.31USDUpdated Aug 28, 2026Other Income / Expense
-301.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 32,166,921.735
Market cap is $7.22B, above the global median of $1.18BNotable
Market cap (USD): 7,216,995,811Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Grifols, S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Demant A/S
Tier 1ProductionApproval-Gated PipelineFlowRule
Biocon Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Glenmark Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CG Oncology, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Huadong Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Samsung Epis Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rhythm Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Erasca, Inc.
Tier 1ProductionApproval-Gated PipelineRule
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk